(Alliance News) - Immunodiagnostic Systems Holdings PLC on Friday said its automated Covid-19 IgG assay test has achieved CE marking and is expected to be available for sale by the end of June.
Shares in the company were up 57% at 330.00 pence each in London.
Unlike many Covid-19 serology assays currently available, this test is a quantitative assay, Immunodiagnostic said. As a result it can determine the antibody concentration in patient serum, rather than giving a 'yes-no' result for prior exposure to the virus.
"Although the clinical level of functional immunity conferred by SARS-CoV-2 IgG antibodies has not yet been determined, we believe quantitative tests may ultimately be valuable in determining immunity status based on the levels of antibody in the blood," the company added.
Immunodiagnostic Chief Executive Jaap Stuut said: "We are pleased that our collaboration with Technogenetics has achieved the important milestone of CE-marking a quantitative, fully automated SARS-CoV-2 antibody test running on the IDS-iSYS analyser. We anticipate launching this assay throughout Europe later this month. IDS has increased production levels of its analysers, and we have sufficient inventory levels to facilitate higher analyser placement levels driven by new customers wishing to run the test."
By Tapan Panchal; tapanpanchal@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
